title: Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report.
abstract: Sorafenib prolongs survival of patients with unresectablehepatocellular carcinoma (HCC). It is likely to be used in human immunodeficiency virus (HIV) infected patients. Interactions between sorafenib and highly active antiretroviral therapy (HAART) have not been studied yet. We report a case of serious adverse effects in anHIV-1 patient co-infected with HBV.
authors.affiliation: Service d'hépatologie, Hôpital Beaujon, APHP, Clichy, France. violaine.ozenne@bjn.aphp.fr
authors.forename: Violaine
authors.initials: V
authors.lastname: Ozenne
authors.forename: Anne
authors.initials: A
authors.lastname: Gervais
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Corrine
authors.initials: C
authors.lastname: Castelnau
authors.forename: Dominique Charles
authors.initials: DC
authors.lastname: Valla
authors.forename: Françoise
authors.initials: F
authors.lastname: Degos
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000821:virology; D004347:Drug Interactions; D015497:HIV-1; D019694:Hepatitis B, Chronic / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib